{
  "id": 17930058,
  "title": "Earnings call transcript: Akums Drugs posts strong Q2 FY 2027 revenue beat",
  "url": "https://urgent.news/2026/11/03/earnings-call-transcript-akums-drugs-posts-strong-q2-fy-2027-revenue",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-03T07:33:23.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/transcripts/earnings-call-transcript-akums-drugs-posts-strong-q2-fy-2027-revenue-beat-93CH-4993697"
  },
  "original_language": "en",
  "account": "Akums Drugs and Pharmaceuticals reported a sharp increase in revenue and a more than doubling of profit in Q2 FY 2027. The company's revenue grew to INR 1,342 crores, surpassing forecasts by around 26.8%, while EBITDA more than doubled to INR 195 crores. The company's contract development and manufacturing operations (CDMO) continued to drive growth, accounting for 83% of quarterly revenue. The company's strong performance was attributed to robust demand across existing and new customers, improved utilization of newer facilities, and a solid order book. Akums also highlighted its expanding product pipeline and growing presence in regulated markets. The stock rallied 1.44% to $743.7 following the earnings release, trading near the top of its 52-week range.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}